A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION

Registry ID
GX29176
Source registry
HEALTH_CANADA
Status
Ongoing
Phase
PHASE3
Study type
INTERVENTIONAL
Sponsor
HOFFMANN-LA ROCHE LIMITED
Start date
2015-11-11
Last update
2015-07-03

Conditions

Related clinical trials

View on source registry